Lenalidomide is effective and safe for the treatment of patients with relapsed multiple myeloma and very severe renal impairment

Cristina Joao, José Freitas, Fernando Gomes, Catarina Geraldes, Ines Coelho, Manuel Neves, Paulo Lucio, Susana Esteves, Graca V Esteves

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Patients with multiple myeloma (MM) and severe renal impairment (SRI) have shorter survival than MM patients without renal failure. Although lenalidomide is a highly active drug, this immunomodulatory agent is frequently neglected in this context due to its predominant renal clearance and, consequently, an increased risk of toxicity. This risk might be overcome with the proper lenalidomide dose adjustment to renal function. This study evaluates the outcomes of 23 relapsed MM patients with SRI (baseline creatinine clearance (CrCl) textless 30 mL/min) treated with lenalidomide-dexamethasone (LenDex), including 56 % (13 patients) under hemodialysis. The median CrCl at start of LenDex was 19 mL/min; an overall response rate (partial response or better) of 56 % was obtained, with a median follow-up from start of LenDex of 52 months (8-79). The median time until maximal response was 4 months, and in 58 % (7/12), the response was longer than 2 years. Nine percent had renal improvement, but all the 13 patients on hemodialysis remained under treatment. LenDex was interrupted in three cases because of adverse events (infections and cutaneous events); 78 % of the patients were on thromboprophylaxis with aspirin. It is important to notice that, after initial dose adjustment of therapy, there should be a continuous process of dose adjustment, taking into account variations in renal function. Furthermore, lenalidomide dose adjustment should be made according to the individual tolerance, even with stable renal function. LenDex dose adjustment, according to these principles, does not negatively impact response and improves treatment tolerance. It has a clear potential to treat this group of patients and to induce long duration of responses [event-free survival (EFS) 20.5 m and overall survival (OS) 42.6 m].
Original languageEnglish
Pages (from-to)931-936
Number of pages6
JournalAnnals Of Hematology
Volume95
Issue number6
DOIs
Publication statusPublished - May 2016

Fingerprint Dive into the research topics of 'Lenalidomide is effective and safe for the treatment of patients with relapsed multiple myeloma and very severe renal impairment'. Together they form a unique fingerprint.

  • Cite this